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Abstract 
Background: Postoperative radiotherapy after breast-conserving surgery (BCS) is the standard in the management 
of breast cancer. The optimal timing for starting postoperative radiation therapy has not yet been well defined. In this 
study, we aimed to evaluate if the time interval between BCS and postoperative radiotherapy is related to the inci-
dence of local and distant relapse in women with early node-negative breast cancer not receiving chemotherapy.
Methods: We retrospectively analyzed clinical data concerning 615 women treated from 1984 to 2010, divided 
into three groups according to the timing of radiotherapy: ≤60, 61–120, and >120 days. To estimate the presence of 
imbalanced distribution of prognostic and treatment factors among the three groups, the χ2 test or the Fisher exact 
test were performed. Local relapse-free survival, distant metastasis-free survival (DMFS), and disease-free survival (DFS) 
were estimated with the Kaplan–Meier method, and multivariate Cox regression was used to test for the independent 
effect of timing of RT after adjusting for known confounding factors. The median follow-up time was 65.8 months.
Results: Differences in distribution of age, type of hormone therapy, and year of diagnosis were statistically signifi-
cant. At 15-year follow-up, we failed to detect a significant correlation between time interval and the risk of local 
relapse (p = 0.09) both at the univariate and the multivariate analysis. The DMFS and the DFS univariate analysis 
showed a decreased outcome when radiotherapy was started early (p = 0.041 and p = 0.046), but this was not con-
firmed at the multivariate analysis (p = 0.406 and p = 0.102, respectively).
Conclusions: Our results show that no correlation exists between the timing of postoperative radiotherapy and the 
risk of local relapse or distant metastasis development in a particular subgroup of women with node-negative early 
breast cancer.
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Background
Breast cancer (BC) is the leading cancer among women 
[1] worldwide. It represented 13.5  % of all cancers in 
Europe in 2012 [2] and the most frequent cause of death 
in women. Several studies have reported a decline in BC 
mortality thanks to early detection and progress in can-
cer treatment [3, 4].
Radiotherapy (RT) after breast-conserving surgery 
(BCS) halves the incidence of local recurrence and 
reduces the cancer-specific death by a sixth. Evidence 
from randomized clinical trials [5–8] and meta-analyses 
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survival, equivalent to those observed with mastectomy 
alone.
The optimal timing for starting postoperative RT is not 
yet well defined. In principle, a delay between surgery and 
the start of RT could allow the growth of clonogenic cells 
in the tumor bed and the development of radioresistance 
[11]. Delays of >8–12 weeks seem to increase the risk of 
local relapse in observational studies, but results are con-
flicting. Moreover, no phase III studies about the optimal 
interval between surgery and radiotherapy are available.
National Canadian clinical practice guidelines rec-
ommend that RT should be given <12  weeks after BCS 
to keep the incidence of local failure and disease-free 
survival (DFS) similar to that of mastectomy [12]. The 
National Cancer Intelligence Network suggests that “the 
time between surgery and the start of radiotherapy should 
be no more than 31  days” [13]. The Merseyside and 
Cheshire cancer network guidelines report that “radio-
therapy should be started within 12 weeks of the date of 
surgery” [14]. The latest Italian guidelines [15] recom-
mend starting RT earlier than 20  weeks after surgery 
if no systemic treatment is given, especially in women 
<40 years of age and/or with positive margins [16, 17].
In this study, we retrospectively analyzed the long-term 
follow-up of 615 women treated with BCS and whole 
breast conventional radiation therapy (WBI) for early BC. 
The aim was to investigate the relationship between wait-
ing time for postoperative RT and the development of 
local relapse and distant metastases.
Methods
We analyzed data concerning 615 patients with early BC 
who underwent WBI with conventional fractionation at 
our institution between December 1984 and December 
2010.
All patients had DCIS-T1-T2, N0, M0 BC, and under-
went BCS (quadrantectomy  ±  sentinel lymph node 
biopsy and/or axillary dissection). After surgery, they 
all received WBI using an isocentric technique with 
two tangential fields, followed by a boost on the tumor 
bed in 89.6 % of cases. The mean dose was 50 Gy (range 
40–60 Gy) for WBI, delivered in 2 Gy fractions five times 
a week. The dose was prescribed at the isocenter, on the 
basis of the ICRU 50 guidelines [18], and the CTV (clin-
ical target volume) was set at a 95  % isodose level. The 
dose to the breast was administered with a ≥6 MV pho-
ton beam; the tumor bed boost was administrated by 
electrons or photon beam to a total dose of 10 Gy in the 
case of negative surgical margins (96.7 %) and to higher 
doses (14–20 Gy) in the case of close or positive margins 
(3.3 %). Surgical margins were considered free if ≥2 mm, 
close if <2  mm, and positive if disease persisted on the 
margin. Patients with close or positive margins refused 
reexcision or did not receive this recommendation by the 
surgeon.
No patient received chemotherapy. Hormone therapy 
(HT) was prescribed in 80.2  % of patients (40.7  % aro-
matase inhibitors, 25.5 % tamoxifen, and 13.8 % tamoxifen 
plus gonadotropine-releasing hormon analog). Almost all 
patients started endocrine therapy before radiotherapy.
Patients without positivity of hormone receptors did 
not receive chemotherapy for age or comorbidities.
The waiting list for BC patients was not formally condi-
tioned by protocols or guidelines concerning risk factors. 
The time of delay was mostly conditioned by the delay in 
referring to the radiotherapy center and the overall wait-
ing list for starting radiotherapy.
After RT, patients were evaluated every 4  months for 
the first 2 years, then every 6 months until the 5th year 
and henceforth every year.
Eighteen women (2.9  %) developed a contralateral 
metachronous epithelial BC.
One patient developed a cutaneous angiosarcoma at 
the level of the breast surgical scar, probably related to 
previous breast irradiation, 9 years after treatment.
All patient subscribed a written consent to treatment. 
This analysis was approved by our institutional Ethics 
Committee.
Statistical methods
For the survival analysis, the BCS date, defined as the 
date of the last surgery on the breast, was used as the 
start of observation, and the date of the last medical fol-
low-up visit was used as the end of the follow-up period. 
Timing of RT was calculated as the interval between BCS 
and the RT start date, defined as the date in which the 
first fraction of RT was administered.
Patients were categorized into three groups accord-
ing to timing of RT (T1: <60 days; T2: 60–120 days; T3: 
>120 days).
The χ2 test or the Fisher exact test, when appropriate, 
was used to calculate intergroup differences of some clin-
ical categorical variables. Results are shown in Table 1.
Survival statistics (Local relapse-free survival—LRFS, 
distant metastasis-free survival—DMFS, and disease-free 
survival-DFS) were estimated with the Kaplan–Meier 
method, and differences between groups were validated 
by the Log-rank test. The multivariate Cox regression 
was used to test for the independent effect of timing of 
RT after adjusting for known confounding factors. The 
results were presented as hazard ratios (HR) with corre-
sponding 95 % confidence intervals. The group with the 
shortest time interval, <60  days, was the reference cat-
egory. Statistical significance was achieved at a p < 0.05.
All the analyses were performed using the Statistical 
Analysis System (SAS Institute, Cary, NC) software.
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Results
The median time of follow-up, defined as the median 
time between BCS and last follow-up, was 65.8  months 
(range 4–179); only 7.5  % of patients had a follow-up 
<6 months. The median waiting time from surgery to the 
start of RT was 111 days (range 21–532 days).
The mean patient age was 58 years (range 21–87).
Differences in distribution of age, type of hor-
mone therapy (HT), and year of diagnosis among the 
three groups were statistically significant (p  <  0.0001, 
p = 0.0006 and p < 0.0001, respectively) (Table 1).
Local relapse‑free survival
Overall, we found 11 disease relapses in the treated breast 
(1.8 %): four of them (36.4 %) in the first group, 4 (36.4 %) 
in the second group, and 3 (27.3 %) in the third group.
The median time between surgery and the occurrence 
of local relapse was 81.7 months (range 16.6–230.4).
Table 1 Distribution of patients on the basis of clinicopathological features and time delay
N number of patients; AI aromatase Inhibitors; LHRH luteinizing hormone-releasing hormone agonists
Variable N ≤60 days N 60–120 days N >120 days p value
N. group 53 298 264
Age
 ≤50 53 31 (58.49) 298 85 (28.52) 264 56 (21.21) <0.0001
 >50 53 22 (41.51) 298 213 (71.48) 264 208 (78.79)
Grading
 G1 32 9 (28.13) 228 63 (27.63) 219 71 (32.42) 0.741
 G2 32 20 (62.50) 228 132 (57.89) 219 118 (53.88)
 G3 32 3 (9.38) 228 33 (14.47) 219 30 (13.70)
Hystologic type
 Ductal infiltrating 52 39 (75.00) 297 225 (75.76) 264 176 (66.67) 0.2576
 Lobular infiltrating 52 5 (9.62) 297 16 (5.39) 264 21 (7.95)
 Ductal in situ 52 4 (7.69) 297 32 (10.77) 264 35 (13.26)
 Other 52 4 (7.69) 297 24 (8.08) 264 32 (12.12)
Margins
 Negative 53 52 (98.11) 298 292 (97.99) 264 251 (95.08) 0.0716
 Close 53 0 (0.00) 298 3 (1.01) 264 1 (0.38)
 Positive 53 1 (1.89) 298 3 (1.01) 264 12 (4.55)
Hormone therapy
 No 34 3 (8.82) 258 14 (5.43) 239 21 (8.79) 0.323
 Yes 34 31 (91.18) 258 244 (94.57) 239 218 (91.21)
Estrogen receptor status
 Negative 35 2 (5.71) 267 14 (5.24) 248 17 (6.85) 0.7418
 Positive 35 33 (94.29) 267 253 (94.76) 248 231 (93.15)
Site
 Right breast 53 24 (45.28) 291 140 (48.11) 257 139 (54.09) 0.2778
 Left breast 53 29 (54.72) 291 151 (51.89) 257 118 (45.91)
T stage
 DCIS 53 5 (9.43) 298 44 (14.77) 264 52 (19.70) 0.2187
 T1 53 38 (71.70) 298 216 (72.48) 264 180 (68.18)
 T2 53 10 (18.87) 298 38 (12.75) 264 32 (12.12)
Hormone therapy type
 None 33 3 (9.09) 258 14 (5.43) 239 21 (8.79) 0.0006
 AI 33 5 (15.15) 258 117 (45.35) 239 128 (53.56)
 Tamoxifen 33 14 (42.42) 258 85 (32.95) 239 58 (24.27)
 LHRH + tamoxifen 33 11 (33.33) 258 42 (16.28) 239 32 (13.39)
Year of diagnosis
 1980–1995 53 16 (30.19) 298 12 (4.03) 264 3 (1.14) <0.0001
 1996–2010 53 37 (69.81) 298 286 (95.97) 264 61 (98.86)
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The Kaplan–Meier method found a LRFS rate of 89.7 % 
for the first group (95 % CI 0.74–0.96), 95.2 % for the sec-
ond (95 % CI 0.86–0.98), and 95.8 % for the third group 
(95 % CI 0.84–0.98). No statistically significant relation-
ship between local relapse and timing of RT was found 
(p = 0.09) (Fig. 1).
When the significant patient variables (age, type of 
HT, and year of diagnosis) shown in Table  1 were con-
sidered in the analysis, the HR for the second and third 
group were 0.28 (95 % CI 0.05–1.58) and 0.58 (95 % CI 
0.09–3.62), respectively, compared with the first group, 
as shown in Table 2. The p value was 0.338.
Distant metastasis‑free survival
In our study, 11 patients (1.8 %) presented distant metas-
tases: 3 (27.3 %) in the group with a delay ≤60 days and 
8 (72.7 %) in the group with a delay of 61–120 days. No 
metastases were found in the third group with a longer 
time delay.
The median time between surgery and the occurrence 
of local relapse was 44.6 months (range 14.4–124.7).
The Kaplan–Meier method found a DMFS rate of 91.3 % 
for the first group (95 % CI 0.73–0.97), 95.2 % for the second 
group (95 % CI 0.90–0.97), and 100 % for the third group.
At the univariate analysis, we found a statistically sig-
nificant difference in the distribution of metastases 
among the three groups (p = 0.041) (Fig. 2).
Nevertheless, when corrected for age, type of HT, and 
year of diagnosis, the HR of the second group was 0.32 
(95 % CI 0.06–1.70). It was not possible to calculate the 
Fig. 1 Kaplan–Meier estimates of local relapse-free survival (LRFS) related to time interval between surgery and radiotherapy (p = 0.09)
Table 2 Adjusted proportional hazard regression results
HR hazard risk; LRFS local relapse-free survival; DMSF distant metastasis-free 
survival; DFS disease-free survival
Timing of RT HR (95 % CI) p
LRFS (days)
 <60 1 0.338
 61–120 0.28 (0.53–1.58)
 >120 0.58 (0.09–3.62)
DMFS (days)
 <60 1 0.406
 61–120 0.32 (0.06–1.70)
 >120 –
DFS (days)
 <60 1 0.102
 61–120 0.36 (0.10–1.24)
 >120 0.18 (0.04–0.91)
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HR for the third group (>120  days) because no metas-
tases occurred in this group (Table  2). The p value was 
0.406.
Disease‑free survival
Twenty-one patients (3.4  %) presented a failure: one 
patient had both local and distant relapse of disease. Six 
disease relapses occurred in the first group (28.6  %), 12 
(57.1 %) in the second group and 3 (14.3 %) in the third 
group.
The median time between surgery and a disease-related 
event, recurrence or metastases, was 67.4 months (range 
14.4–230.4).
The DFS rate calculated with the Kaplan–Meier 
method was 85.7  % (95  % CI 0.70–0.93) for the first 
group, 90.5  % for the second (95  % CI 0.82–0.95), and 
95.8 % for the third group (95 % CI 0.85–0.98). This dif-
ference was marginally statistically significant (p = 0.046) 
(Fig. 3).
Multivariate analysis confirmed that timing of RT is not 
an independent prognostic factor (p =  0.102) (Table 2). 
The HRs for the second and third group were 0.36 (95 % 
CI 0.10–1.24) and 0.18 (95 % CI 0.04–0.91), respectively, 
compared with the first group.
An analysis aiming to find correlation between local 
relapse or distant metastases and certain characteristics, 
as patient age, status of surgical margins or tumor histol-
ogy, grade, and stage, was conducted, but no statistically 
significant differences were found among these subgroups.
Discussion
The interval between BCS and postoperative RT in breast 
cancer treatment can significantly change. Causes of this 
variation could be patient compliance and socioeconomic 
status; geographic distribution of radiotherapy centers; 
long waiting lists; characteristics of patients and their 
cancer (age, prognostic factors, presence of comorbidi-
ties, etc.) [19], and surgical complications (slow wound 
healing, inflammation, or infections). Moreover, the wait-
ing time for radiotherapy has increased dramatically dur-
ing the last decades [20, 21] due to the increased demand 
for radiation treatments.
In theory, an excessive time to RT could be associated 
with an increased risk of local recurrence and with a 
subsequent increased risk of metastasis. Some radiobio-
logical models [22] have shown a small decrease in local 
control of 1–2 % per month’s delay in treatment.
However, clinical data are not always consistent with 
this theory. No phase III trials have been published, but 
only several retrospective analyses: some experiences 
showed a positive association, while others did not find a 
clear correlation.
Fig. 2 Kaplan–Meier estimates of distant metastasis-free survival (DMFS) related to time interval between surgery and radiotherapy (p = 0.041)
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One of the first studies on the relationship between 
waiting time for radiotherapy and clinical outcomes 
was conducted in 1985 at the Institut Gustave Roussy 
in France by Clarke et  al [23]. They reviewed 436 
patients with T1 and small T2 breast carcinoma, find-
ing a significant increase in local relapse in the group 
that received radiotherapy more than 7 weeks after sur-
gery. These results were not confirmed on multivariate 
analysis.
One of the largest studies published reviewed data 
concerning 13,907 women ≥65 years with stage I–II BC 
diagnosed and treated between 1991 and 1999 and not 
receiving chemotherapy, extracted from the surveillance, 
epidemiology, and end results (SEER) registry [24]. The 
Authors concluded that “patients who do not receive 
RT until more than 12  weeks after BCS appear to have 
poorer survival.” A successive SEER database analy-
sis conducted in 2010 [25] showed that intervals over 
6  weeks were associated with an increased incidence of 
local recurrence.
Many other retrospective studies found a significant 
correlation between a long RT delay and increased rate 
of local relapse, with or without impact on survival, in 
the same cohort of patients [16, 26–28]. Simultaneously, 
another group of retrospective analyses conducted on 
similar patients failed to find a significant variation of 
these endpoints [29–34].
Contrary to all this evidence, a recent retrospec-
tive analysis [35] on 1107 women with early-stage BC 
without lymph node metastases or adjuvant systemic 
therapies found a significantly decreased DMFS and 
disease-specific survival in the tertile that started radio-
therapy early after BCS (<45  days) compared with the 
other two tertiles (45–56 and 57–112 days), without dif-
ferences in local control. The Authors attributed these 
results to residual confounding factors (age and prog-
nostic factors) that could lead the physician to start 
radiotherapy early in high-risk patients. Another proba-
bility is that starting radiotherapy too early could induce 
vascular damage, a delay in stromal cell growth, and an 
increase in tumor cell damage: these mechanisms could 
lead to a easier spread of metastatic cells, as suggested 
in a previous study on radiation induced metastatic 
spread and angiogenesis.
Further information on the optimal timing of RT in 
early-stage cancer treated with sole Radiotherapy could 
be extracted from studies that also included patients with 
advanced-stage BC, through the analysis of subgroups. 
Even in these studies results are not unequivocal, rang-
ing from the nonexistence of association [17, 36, 37] to a 
Fig. 3 Kaplan–Meier estimates of disease-free survival (DFS) related to time interval between surgery and radiotherapy (p = 0.046)
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mild [38] or significant [39–45] correlation between RT 
delay and local recurrence rate.
Some Authors have tried to summarize these conflict-
ing results through meta-analysis and reviews, but final 
analysis remains conflicting.
The critical review conducted by Hebert-Croteau 
published between 1985 and 2000 reported a nonsig-
nificant association between time interval and the risk 
of local recurrence or death related to BC [46]. In con-
trast, a meta-analysis by Huang et  al [47] published in 
2003 and including 7401 BC patients showed a 1.62-fold 
increase in local recurrence rate when radiotherapy was 
administered >8 weeks after BCS. In another review, Ruo 
Redda et al. [48] suggested that, in the group of patients 
that do not need any treatments other than RT, the time 
interval should not exceed 8 weeks. A more recent sys-
tematic review conducted by Chen et  al. [49] evaluated 
time interval to RT as a continuous variable, showing 
an increase of the RR of local recurrence of 1.11 every 
month after BCS. An association between waiting time 
and distant metastases or overall survival did not emerge. 
The most recent systematic review by Tsoutsou et al. [50] 
found that an interval of more than 8–12 weeks increased 
local recurrence rates when RT was administered as the 
sole adjuvant modality.
In our study, we aimed to explore the correlation 
between the delay of postoperative RT and the devel-
opment of local recurrence and distant metastases in 
women with node-negative T1–T2 BC treated with 
RT, with/without HT but without chemotherapy. We 
divided the 615 patients into three subgroups according 
to the timing of RT (T1: <60 days; T2: 60–120 days; T3: 
>120 days). The majority of patients were in the second 
group.
Our experience failed to detect a significant correlation 
between BCS-to-RT time interval and the risk of local 
relapse in early-stage BC patients (p = 0.09). This lack of 
significance was confirmed at the multivariate analysis 
adjusted for age and type of HT, indicating that the fail-
ure to find a univariate relationship between timing of RT 
and BC local recurrence was not imputable to an uneven 
distribution of these two variables.
On the other hand, we found an unexpected but sig-
nificant inverse correlation at the univariate analysis 
between timing of RT and the risk of distant metastases 
development. In particular, at the Kaplan–Meier analy-
sis, the DMFS was 91.3 % for the group that received RT 
prior to 60 days, 95.2 % for the group who received RT 
between 61 and 120 days after surgery, and 100 % for the 
group who received RT more than 120  days after BCS 
(p = 0.041). The outcome seemed to be worse in patients 
who started RT early (<60 days after surgery). However, 
this correlation was not confirmed at the multivariate 
analysis (HR T2: 0.32; 95  % CI 0.06–1.70, p  =  0.406) 
when age of patients, type of HT, and year of diagnosis 
were considered.
Similarly, the DFS seemed to be correlated to tim-
ing of RT at the univariate analysis with a marginal sta-
tistical significance, (T1: 85.7 %, T2: 90.5 %; T3: 95.8 %; 
p = 0.046), apparently confirming the worse outcome of 
patients in the first group. Also in this case, any correla-
tion was lost when analysis was adjusted for known con-
founding factors (HR T2: 0.36; 95 % CI 0.10–1.24; HR T3: 
0.18, 95 % CI 0.04–0.91, p = 0.102).
These results seem to be related to an unbalanced dis-
tribution of two main variables (age and year of diagnosis) 
among the three groups. In turn, the third confounding 
variable (type of HT) is often strictly dependent on the 
age of patients. Probably, these factors operated as real 
confounding factors when DMFS and overall DFS are 
considered. In particular, we observed a prevalence of 
young women, with a consequent younger median age, 
in the first group compared with the other two groups. 
It is possible that physicians involuntarily expedited RT 
for cases they perceived to be at higher risk of local or 
distant recurrence, such as young women. The correla-
tion between age and rate of local [5, 10, 51] and distant 
[52] relapse, especially visceral metastases [53], has been 
demonstrated in several large studies and is often consid-
ered by physicians during the first evaluation of a breast 
cancer patient.
Moreover, in the first group, we found a greater pro-
portion of patients treated in the 1980s and early 90s 
compared with the other two groups, probably due to 
the lesser impact of waiting lists in past years. This find-
ing could justify the worse outcome in terms of DMFS 
and DFS which emerged for the T1 group at the uni-
variate analysis: when these BC patients were treated, 
RT technology was not advanced: this could lead to an 
under-dosage or a partial miss of the radiotherapy tar-
get. Moreover, in past decades, accurate guidelines about 
systemic treatment of BC were not available: nowadays, 
adjuvant chemotherapy is more often prescribed [54], so 
it is possible that patients treated in the first years of our 
analysis would have to be treated with more aggressive 
therapies because they presented high-risk features.
Finally, we know that local and distant relapse usu-
ally occur after several years: patients in the T1 group, 
treated in the 80s and early 90s, are more likely to 
develop relapses because of their longer follow-up rather 
than because of a real correlation with timing of RT. All 
these confounding factors, considered in the multivariate 
analysis, could explain the lack of significant correlation 
between timing of RT and all the events considered.
Evidently, our study has some limits intrinsic to its 
retrospective nature, such as the bias regarding patient 
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selection and their unequal distribution among the three 
timing groups.
Moreover, although we followed patients for a long 
time (until 15 years), the median follow-up is only about 
6  years, because of the large time of accrual and the 
presence of patients who did not attended the follow-
up program. Local recurrence in BC could develop also 
10–15 years after BCS, so a longer follow-up is requested 
to obtain more realistic data.
Conclusions
Our results showed that there is no correlation between 
the BCS-to-RT interval time and the risk of local relapse 
or distant metastases in a particular subset of node-nega-
tive early-stage BC patients not receiving chemotherapy. 
However, our results are limited by the retrospective 
nature of the study, so they should be validated by ran-
domized studies or well selected meta-analysis, with the 
aim of filling the gap in clinical evidence about the opti-
mal time interval between BCS and PORT.
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